You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: ALTRAVAX, INC Topic: NIAID
DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: POINT DESIGNS, LLC Topic: NICHD
The Point PartialA Ratcheting Prosthetic Partial FingerUsing Advanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop a purely mechanicalratcheting prosthetic partial fingerthe Point Partialwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s proxi ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: SPIKEGADGETS, INC. Topic: 101
Psychiatric disorders give rise to aberrant patterns of activity within the complex neural circuits of our brainsYetthe exact nature of these abnormal patterns is often unknown to developers of new treatmentsThe goal of this project is to enable circuit oriented research of neuropsychiatric diseases using rodent disease modelsThe long term objective is to catalyze the discovery of new therapeutic ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 300
DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: REMD BIOTHERAPEUTICS INC. Topic: NIDDK
DESCRIPTION provided by applicant Fast Track Insulin remains the primary and often the only treatment for type diabetes mellitus T D However it is associated with chronic iatrogenic hyperinsulinemia secondary hyperlipidemia higher incidence and severity of cardiovascular complications and life threatening hypoglycemia events A higher mortality vs due to cardiovascular ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NeoVative, Inc. Topic: NHLBI
DESCRIPTION provided by applicant Asthma is the most common chronic illness of childhood but many children have poorly controlled symptoms causing morbidities hospitalizations and costs The first step toward good asthma control is accurate assessment of symptoms Recall of the frequency and severity of symptoms is the cornerstone of asthma assessment Unfortunately recall by parents or ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's diseaseSBC: ASTROCYTE PHARMACEUTICALS INC. Topic: NIA
PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: ASTROCYTE PHARMACEUTICALS INC. Topic: 105
DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit n ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: RIO PHARMACEUTICALS, INC. Topic: NINDS
PROJECT SUMMARYTraumatic Brain InjuryTBIis one of the most significant Public Health trauma diseases of our timeDiagnoses of various TBI forms rely on patient self reportingestablished clinical rating scalesand multimodality imaging to an extentTBI elicits complexheterogeneous pathological eventsincluding mechanical injuryhemorrhageand progressive secondary processes such as central and peripheral ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: CORTICOMETRICS LLC Topic: NIA
DESCRIPTION provided by applicant Alzheimerandapos s disease AD the most common type of dementia is a devastating disease with no available treatment or prevention The current lifetime risk for a year old individual is estimated to be around Given current projections over million individuals will be diagnosed with Alzheimerandapos s disease by As the development of the ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health